Video
Dr John C. Morris Highlights Exciting Developments in Lung Cancer Immunotherapy
The introduction of the immune regulatory checkpoint inhibitors and their impressive results is what John C. Morris, MD, professor of hematology and oncology at the University of Cincinnati, finds most exciting in the area of lung cancer immunotherapy.
The introduction of the immune regulatory checkpoint inhibitors and their impressive results is what John C. Morris, MD, professor of hematology and oncology at the University of Cincinnati, finds most exciting in the area of lung cancer immunotherapy.
Ongoing studies are using these inhibitors in combination with each other and with cancer vaccines. Early results of one of his own clinical trials of the HyperAcute lung vaccine has shown the vaccine to be safe and that very heavily pre-treated patients may benefit from it,
"The results will be very interesting if it shakes out that the vaccine has results that are either equal to or better than the standard of care," Dr Morris said. He added, "Chemotherapy has the typical chemotherapy side effects; the vaccine has had none of these side effects."
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
